

DAFTAR PUSTAKA

1. Brevini T, Tysoe OC, Sampaziotis F. Tissue engineering of the biliary tract and modelling of cholestatic disorders. Vol. 73, *Journal of Hepatology*. Elsevier B.V.; 2020. p. 918–32.
2. Aldana AJG, Tapias M, Mindiola AL. Diagnostic and therapeutic approach for cholestasis in the adult. *Rev Colomb Gastroenterol*. 2020;35(1):76–86.
3. Hilscher MB, Kamath PS, Eaton JE. Cholestatic Liver Diseases: A Primer for Generalists and Subspecialists. *Mayo Clin Proc [Internet]*. 2020;95(10):2263–79. Available from: <https://doi.org/10.1016/j.mayocp.2020.01.015>
4. Christopher F. McNicoll, Alyssa Pastorino, Umer Farooq, Mary J. Froehlich CRSH. Choledocolithiasis [Internet]. StatPearls Publishing. 2023. p. 1–18. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK441961/>
5. Giron F, Del U, Lina R, Rodríguez M, Universidad MV, Rosario D, et al. Intermediate Risk of Choledocolithiasis: Are We on the Right Path? 2021; Available from: <https://doi.org/10.21203/rs.3.rs-745379/v1>
6. Chang YR, Jang JY, Kwon W, Park JW, Kang MJ, Ryu JK, et al. Changes in demographic features of gallstone disease: 30 years of surgically treated patients. *Gut Liver*. 2013;7(6):719–24.
7. Azriyantha MR, Ambiar Manjas. Characteristics of Cholelithiasis Patients in Dr. Achmad Mochtar General Hospital Bukittinggi on January 2019 - December 2020. *Biosci Med J Biomed Transl Res*. 2022;6(2):1405–10.
8. Lee YT, Sung J. Choledocholithiasis. In: *ERCP*. Elsevier; 2008. p. 357–66.
9. Orman S, Senates E, Ulasoglu C, Tuncer I. Accuracy of imaging modalities in choledocholithiasis: A real-life data. *Int Surg*. 2019;103(3–4):177–83.
10. Pollock G, Minuk GY. Diagnostic considerations for cholestatic liver disease. *J Gastroenterol Hepatol*. 2017;32(7):1303–9.
11. Benarroch-Gampel J, Boyd CA, Sheffield KM, Townsend CM, Riall TS. Overuse of ct in patients with complicated gallstone disease. *J Am Coll Surg [Internet]*. 2011;213(4):524–30. Available from: <http://dx.doi.org/10.1016/j.jamcollsurg.2011.07.008>
12. Damnjanovic Z, Jovanovic M, Nagorni A, Radojkovic M, Sokolovic D, Damnjanovic G, et al. Correlation of inflammation parameters and biochemical markers of cholestasis with the intensity of lipid peroxidation in patients with choledocholithiasis. *Vojnosanit Pregl*. 2013;70(2):170–6.

13. Astrid Kusters SJK. The role of inflammation in cholestasis – clinical and basic aspects. *Semin Liver Dis.* 2013;30(2):186–94.
14. Damnjanović Z, Jovanović M, Nagorni A, Sokolović D, Đinđić B, Damnjanović G, et al. Correlation Between Inflammatory Parameters and Markers of Cholestasis in Patients With Choledocholithiasis. *Acta Medica Median.* 2014;53(2):28–32.
15. Zajic S, Damnjanovic Z, Stojanovic M, Visnjic M, Dencic S, Ilic D, et al. Original article BIOCHEMICAL MARKERS IN PATIENTS WITH EXTRAHEPATIC. 2007;(2):5–12.
16. Tetangco EP, Shah N, Arshad HMS, Raddawi H. Markedly elevated liver enzymes in choledocholithiasis in the absence of hepatocellular disease: Case series and literature review. *J Investig Med High Impact Case Reports.* 2016;4(2):4–6.
17. Poupon R. Liver alkaline phosphatase: A missing link between cholestasis and biliary inflammation. *Hepatology.* 2015;61(6):2080–90.
18. Kumar P, Ratnesh K, Kumar P. Section : Surgery To Determine the Prediction of Choledocholithiasis by Sex-related Differences in Patients with Symptomatic Gallstones. 2020;7(8):7–9.
19. Ioana Baiu, MD M, Mary T. Hawn, MD M. Choledocholithiasis occurs when a gallstone blocks the common bile duct and bile cannot flow past it, instead backing up into the liver. *Jamapatient Page.* 2018;320(14):2021.
20. Pasquale Cianci, Enrico Restin. Management of cholelithiasis with choledocholithiasis: Endoscopic and surgical approaches. *World J Gastroenterol* [Internet]. 2021;27(28):4484–745. Available from: <https://www.wjgnet.com/bpg/gerinfo/240>
21. Wu Y, Xu CJ, Xu SF. Advances in risk factors for recurrence of common bile duct stones. *Int J Med Sci.* 2021;18(4):1067–74.
22. Lu L. Guidelines for the Management of Cholestatic Liver Diseases (2021). *J Clin Transl Hepatol* [Internet]. 2022;10(4):757–69. Available from: <https://www.doi.org/10.14218/JCTH.2022.00147>
23. Wang DQ-H, Neuschwander-Tetri BA, Portincasa P. The Biliary System, Second Edition. *Colloq Ser Integr Syst Physiol From Mol to Funct.* 2016;8(5):i–178.
24. John MHHBS. Physiology, Bile Secretion. *Treasure Isl StatPearls Publ* [Internet]. 2022;1–16. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK470209/>

25. Dosch AR, Imagawa DK, Jutric Z. Bile Metabolism and Lithogenesis: An Update. *Surg Clin North Am* [Internet]. 2019;99(2):215–29. Available from: <https://doi.org/10.1016/j.suc.2018.12.003>
26. Goral V. Gallstone etiopathogenesis, Lith and Mucin genes and new treatment approaches. *Asian Pacific J Cancer Prev*. 2016;17(2):467–71.
27. Sun H, Warren J, Yip J, Ji Y, Hao S, Han W, et al. Factors Influencing Gallstone Formation: A Review of the Literature. *Biomolecules*. 2022;12(4):1–13.
28. Inamullah G, Muhammad Ali S, Khan B, Shahid F, Aftab Z, Al-Tarakji M, et al. Management of Common Bile Duct Stones: A Comprehensive Review. *Biomed Sci*. 2020;6(4):102.
29. Kujawski K, Stasiak M, Rysz J. Qualification for endoscopic retrograde cholangiopancreatography in the diagnosis and treatment of extrahepatic cholestasis caused by choledocholithiasis. *Arch Med Sci*. 2015;11(6):1213–6.
30. Quispe-Mauricio A. Extraintestinal manifestations (EIM) associated with inflammatory bowel disease (IBD): What radiologists should know. 2017;(March). Available from: <https://www.researchgate.net/publication/314079365>
31. Makmun D, Fauzi A, Shatri H. Sensitivity and specificity of magnetic resonance cholangiopancreatography versus endoscopic ultrasonography against endoscopic retrograde cholangiopancreatography in diagnosing choledocholithiasis: The Indonesian experience. *Clin Endosc*. 2017;50(5):486–90.
32. Kitagawa S, Miyakawa H. Gallstones Within the Pancreatic Duct: An Underlying Pancraticobiliary Maljunction. *ACG Case Reports J*. 2016;3(1):160–1.
33. Emmady VEEPD. Histology, Monocytes. *Treasure Isl StatPearls Publ*. 2022;
34. Schneider L, Marcondes NA, Hax V, da Silva Moreira IF, Ueda CY, Piovesan RR, et al. Flow cytometry evaluation of CD14/CD16 monocyte subpopulations in systemic sclerosis patients: a cross sectional controlled study. *Adv Rheumatol*. 2021;61(1).
35. Prame Kumar K, Nicholls AJ, Wong CHY. Partners in crime: neutrophils and monocytes/macrophages in inflammation and disease. *Cell Tissue Res*. 2018;371(3):551–65.
36. Jakubzick C V., Randolph GJ, Henson PM. Monocyte differentiation and antigen-presenting functions. *Nat Rev Immunol* [Internet]. 2017;17(6):349–62. Available from: <http://dx.doi.org/10.1038/nri.2017.28>

37. Lee SJ, Choi EK, Seo KW, Bae JU, Park SY, Kim CD. TLR4-mediated expression of Mac-1 in monocytes plays a pivotal role in monocyte adhesion to vascular endothelium. *PLoS One*. 2014;9(8):1–8.
38. Wammers M, Schupp AK, Bode JG, Ehling C, Wolf S, Deenen R, et al. Reprogramming of pro-inflammatory human macrophages to an anti-inflammatory phenotype by bile acids. *Sci Rep*. 2018;8(1):1–15.
39. Tacke F. Targeting hepatic macrophages to treat liver diseases. *J Hepatol* [Internet]. 2017;66(6):1300–12. Available from: <http://dx.doi.org/10.1016/j.jhep.2017.02.026>
40. Morita Y, Yoshidome H, Kimura F, Shimizu H, Ohtsuka M, Takeuchi D, et al. Excessive Inflammation but Decreased Immunological Response Renders Liver Susceptible to Infection in Bile Duct Ligated Mice. *J Surg Res*. 2008;146(2):262–70.
41. Sheinenzon A, Shehadeh M, Michelis R, Shaoul E, Ronen O. Serum albumin levels and inflammation. *Int J Biol Macromol* [Internet]. 2021;184(May):857–62. Available from: <https://doi.org/10.1016/j.ijbiomac.2021.06.140>
42. Soeters PB, Wolfe RR, Shenkin A. Hypoalbuminemia: Pathogenesis and Clinical Significance. *J Parenter Enter Nutr*. 2019;43(2):181–93.
43. A.B. Olokoba , B.J. Bojuwoye , L.B. Olokoba , K.T. Braimoh AKI and AAA. Relationship Between Gallstone Disease and Liver Enzymes. *Medwell Publ*. 2009;3(1):1–3.
44. Yurgaky-Sarmiento J, Otero-Regino W, Gómez-Zuleta M. Elevated transaminases: A new tool for the diagnosis of choledocholithiasis. A case control study. *Rev Colomb Gastroenterol*. 2020;35(3):319–28.
45. Washington IM, Van Hoosier G. *Clinical Biochemistry and Hematology. The Laboratory Rabbit, Guinea Pig, Hamster, and Other Rodents*. 2012. 57–116 p.
46. Aulbach AD, Amuzie CJ. Biomarkers in Nonclinical Drug Development [Internet]. Second Edi. *A Comprehensive Guide to Toxicology in Nonclinical Drug Development*. Elsevier Inc.; 2016. 447–471 p. Available from: <http://dx.doi.org/10.1016/B978-0-12-803620-4.00017-7>
47. Conway ME. Aminotransferases. *Amin Acids Hum Nutr Heal*. 2011;24–50.
48. Hayat JO, Loew CJ, Asress KN, McIntyre AS, Gorard DA. Contrasting liver function test patterns in obstructive jaundice due to biliary structures and stones. *QJM - Mon J Assoc Physicians*. 2005;98(1):35–40.
49. John DLTSMZS. Alkaline Phosphatase. *Treasure Isl StatPearls Publ*. 2022;1–28.

50. Hassan L, Sadiq T, Naveed MR. Positive predictive value of raised serum alkaline phosphatase in predicting choledocholithiasis taking operative findings as gold standard. *Pakistan J Med Heal Sci*. 2018;12(4):1560–2.
51. Milik A, Hryniewicz E. On translation of LD, IL and SFC given according to IEC-61131 for hardware synthesis of reconfigurable logic controller. *IFAC Proc Vol*. 2014;19(1):4477–83.
52. Degnim AC, Hoskin TL, Brahmbhatt RD, Warren A, Loprinzi M, Pavey ES, et al. Standard Definitions and Common Data Elements for Clinical Trials in Patients With Alcoholic Hepatitis: Recommendation From the NIAAA Alcoholic Hepatitis Consortia. *Gastroenterology*. 2015;21(10):3240–8.
53. Tu T, Patel K, Shackel NA. Viral Hepatitis [Internet]. *Genomic and Precision Medicine: Primary Care: Third Edition*. Elsevier Inc.; 2017. 317–340 p. Available from: <http://dx.doi.org/10.1016/B978-0-12-800685-6.00017-5>
54. Tajiri K, Shimizu Y. Practical guidelines for diagnosis and early management of drug-induced liver injury. *World J Gastroenterol*. 2008;14(44):6774–85.
55. Cederholm T, Barazzoni R, Austin P, Ballmer P, Biolo G, Bischoff SC, et al. ESPEN guidelines on definitions and terminology of clinical nutrition. *Clin Nutr*. 2017;36(1):49–64.
56. Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J, et al. Oncotarget 7204 www.impactjournals.com/oncotarget Inflammatory responses and inflammation-associated diseases in organs. *Oncotarget* [Internet]. 2018;9(6):7204–18. Available from: www.impactjournals.com/oncotarget/
57. Mangaonkar AA, Tande AJ, Bekele DI. Differential Diagnosis and Workup of Monocytosis: A Systematic Approach to a Common Hematologic Finding. *Curr Hematol Malig Rep*. 2021;16(3):267–75.
58. Costa PHP, Sousa JHB de, Lima IT de, Noronha MAN, Aranha GL, Arienzo VP, et al. The use of serum alkaline phosphatase as a choledocholithiasis marker to mitigate the cost of magnetic resonance cholangiography. *Einstein (Sao Paulo)*. 2023;21:eAO0204.
59. Madrigano J. Approach To A Patient With Elevated Serum Alkaline Phosphatase. *Occup Env Med*. 2008;23(1):1–7.
60. Triwikatmani C. The Difference Of Alkaline Phosphatase, Bilirubin, And Gamma Glutamyl Transferase Level In Different Gallstone Location Of Gallstone Patient In Rsup Dr Sardjito. *Perpust Univ Gadjah Mada*. 2014;
61. Guillot A, Guerri L, Feng D, Kim SJ, Ahmed YA, Paloczi J, et al. Bile acid-activated macrophages promote biliary epithelial cell proliferation through

integrin $\alpha\beta6$ upregulation following liver injury. *J Clin Invest*. 2021;131(9).

62. Gulumsek E, Yesildal F, Avci BS, Yigitdol I, Aktas B, Kara B, et al. Monocyte to high-density lipoprotein and derived neutrophil to lymphocyte ratio in patients with acute pancreatitis are associated with the severity of the disease. *Int J Med Biochem*. 2022;5(2):77–83.
63. Lao Y, Li X, Zhou W, Zhu H, Jiang Y, Li S, et al. The clinical value of the monocyte to high-density lipoprotein cholesterol ratio and alkaline phosphatase-to-platelet ratio in primary biliary cholangitis. *Medicine (Baltimore)*. 2023;102(41):e35454.
64. Johny Salem, Walaa Arja, Jennifer Aoun, Nourhane Obeid, Anna-maria Abinehme, Nour Gharib, Tala Ghorayeb SF. Clinical Correlation Between Pre and Post ERCP Laboratory Values. *Int J Clin Res*. 2022;3(1).
65. Li G. Diagnostic value of liver function enzymes for choledocholithiasis. 2016;9(7):13014–20.
66. Küçük İ, Yazgan Y, Tural E, Yıldırım İ, Akbaş Şimşek T, Çakır Güney B KM. Can inflammatory indexes predict the spontaneous passage of common bile duct stones? *Scott Med J* [Internet]. 2023; Available from: <https://pubmed.ncbi.nlm.nih.gov/37691607/>
67. Karaca Bozdağ Z, Bozdağ E, Sonmez S, Pamukcu Beyhan A, Atasever A. Comparison of the cystocholedochal angle in patients with choledocholithiasis and only cholelithiasis. *Clin Anat*. 2023;36(4):675–86.
68. Header DA, Aboelwafa RA, Elkeleny MR, Bedewy ES, Ellakany AI. C-reactive protein/albumin ratio (CAR) as a marker for detecting acute severe ulcerative colitis in Egyptian patients. *Rev Gastroenterol México (English Ed)* [Internet]. 2022;87(4):447–54. Available from: <https://doi.org/10.1016/j.rgm xen.2022.06.007>
69. Peng W, Shen J, Dai J, Leng S, Xie F, Zhang Y, et al. Preoperative aspartate aminotransferase to albumin ratio correlates with tumor characteristics and predicts outcome of hepatocellular carcinoma patients after curative hepatectomy: a multicenter study. *BMC Surg* [Internet]. 2022;22(1):1–10. Available from: <https://doi.org/10.1186/s12893-022-01751-4>
70. Zhang F, Lu S, Tian M, Hu K, Chen R, Zhang B, et al. Albumin-to-alkaline phosphatase ratio is an independent prognostic indicator in combined hepatocellular and cholangiocarcinoma. *J Cancer*. 2020;11(17):5177–86.